HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation

Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Peslak, Scott A., Khandros, Eugene, Huang, Peng, Lan, Xianjiang, Geronimo, Carly L., Grevet, Jeremy D., Abdulmalik, Osheiza, Zhang, Zhe, Giardine, Belinda M., Keller, Cheryl A., Shi, Junwei, Hardison, Ross C., Blobel, Gerd A.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Red Cells, Iron, and Erythropoiesis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/
https://ncbi.nlm.nih.gov/pubmed/32956454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires